Printer Friendly

THE JOURNAL TRANSFUSION PUBLISHES ARTICLE ON TREATMENT OF REFRACTORINESS TO PLATELET TRANSFUSION WITH IMRE CORPORATION'S PROSORBA COLUMN

 SEATTLE, March 18 /PRNewswire/ -- IMRE Corporation (NASDAQ: IMRE), a leader in the field of immunoadsorption, announced today that the journal Transfusion, in its March 1993 issue, reported the treatment of ten thrombocytopenic patients who were refractory to platelet transfusion due to alloimmunization with IMRE Corporation's PROSORBA(R) column. Following treatments, six of the ten patients maintained average daily platelet counts that were two to eight times their pretreatment counts, thus, allowing their blood to clot normally.
 Refractory to platelet transfusion due to alloimmunization is a type of immune-mediated blood clotting complication of leukemia therapy, bone marrow transplantation, and other disorders in which platelet (the blood clotting elements) transfusion is required to prevent bleeding. It affects approximately 60,000 patients in the United States alone. In the independent study, which was reported by the Department of Laboratory Medicine and Pathology at the University of Minnesota, the ten patients had undergone bone marrow therapy, were refractory to platelet transfusion, and were not responsive to chemotherapy.
 Following treatment with the PROSORBA column, six of the ten patients achieved increases in platelet counts accompanied by improved responsiveness to platelet transfusion. These findings led the authors of the article to conclude that PROSORBA column treatment may be an effective means of increasing platelet counts and platelet transfusions in certain patients who are refractory to platelet transfusion due to platelet-reactive antibodies.
 The PROSORBA column was developed by IMRE scientists. It is a disposable, single-use cylindrical canister about three inches in diameter and three inches in height. The column contains a patented matrix comprised of solid granules of silica bound to a molecule, protein A, which can remove immune suppressor molecules from a patient's blood plasma. Following removal of this immune suppressor, the body's immune system acts more normally and can combat immune-related diseases. In the two-hour procedure, a patient's plasma is separated from the blood cells, passed through the column, re-combined with the cells, and re-infused into the same patient.
 IMRE Corporation received FDA approval in 1987 to market the PROSORBA column for the treatment of immune thrombocytopenic purpura (ITP), an immune-related bleeding disorder. The company is currently conducting clinical trials in rheumatoid arthritis, other autoimmune diseases, and certain cancers.
 -0- 3/18/93
 /CONTACT: Lois Yoshida of IMRE Corporation, 206-298-9400/


CO: IMRE Corporation ST: Washington IN: MTC SU: PDT

LD-KW -- NY007 -- 7295 03/18/93 08:30 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 18, 1993
Words:393
Previous Article:FLEET RESTRUCTURES MANAGEMENT ALONG FUNCTIONAL LINES AS FOUR ARE PROMOTED TO TOP-LEVEL POSITIONS; GREATER EFFICIENCIES EXPECTED
Next Article:COUNTRYWIDE CREDIT'S FOURTH QUARTER EARNINGS RISE 78 PERCENT; BOARD DECLARES CASH AND STOCK DIVIDENDS
Topics:


Related Articles
IMRE ANNOUNCES PUBLICATION IN NEW ENGLAND JOURNAL OF MEDICINE
CANCER PUBLISHES RESULTS OF TREATMENT OF C-TTP/HUS WITH IMRE CORPORATION'S PROSORBA COLUMN
THE LANCET PUBLISHES CASE STUDY ON EFFECTIVENESS OF IMRE'S PROSORBA(R) COLUMN
PIXYKINE EASES COMPLICATIONS OF CANCER TREATMENT; SINGLE AGENT AFFECTS MULTIPLE BLOOD CELL LINEAGES
JOURNAL OF RHEUMATOLOGY PUBLISHES RESULTS OF TREATMENT OF RHEUMATOID ARTHRITIS WITH IMRE CORPORATION'S PROSORBA COLUMN
IMRE CORPORATION'S PROSORBA(R) COLUMN SHOWN BENEFICIAL IN TREATING NEUROLOGICAL CONDITIONS
Cerus and Baxter Announce Results of European Phase 3 Trial of Their Intercept Platelet System for Pathogen Inactivation.
CERUS AND BAXTER ANNOUNCE RESULTS OF EUROPEAN PHASE 3 TRIAL OF THEIR INTERCEPT PLATELET SYSTEM FOR PATHOGEN INACTIVATION.
CERUS/BAXTER REPORT GOOD RESULTS FOR EUROPEAN PHASE 3 TRIAL.
CERUS/BAXTER APPLY FOR CE MARK FOR INTERCEPT PLATELET SYSTEM.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters